-
-
-
-
-
-
-
Galapagos announces full year 2022 results and outlook for 2023
-
-
-
-
-
-
-
Galapagos demonstrates regulatory and commercial progress in Q1 2022
-
-
-
-
-
-
-
Ryvu Therapeutics reports financial results for 2020
-
-
-
-
-
-
-
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)
-
-
-
-
-
-
-
On track for clinical read-outs and commercial readiness in 2020
-
-
-
-
-
-
-
S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high
-
-
-
-
-
-
-
Firmly on our way to becoming a fully integrated biopharma company
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

